Patents by Inventor Michael Torgov

Michael Torgov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
    Publication number: 20230346968
    Abstract: Antibody drug conjugates (ADC’s) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC’s of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: December 14, 2022
    Publication date: November 2, 2023
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventors: Daulet SATPAYEV, Robert Kendall MORRISON, Karen Jane Meyrick MORRISON, Jean GUDAS, Aya JAKOBOVITS, Michael TORGOV, Zili AN
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 11559582
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: January 24, 2023
    Assignees: AGENSYS, INC., SEAGEN INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
    Publication number: 20210283268
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: December 15, 2020
    Publication date: September 16, 2021
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventors: Daulet SATPAYEV, Robert Kendall MORRISON, Karen Jane Meyrick MORRISON, Jean GUDAS, Aya JAKOBOVITS, Michael TORGOV, Zili AN
  • Light chain variable regions
    Patent number: 11033634
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: June 15, 2021
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 10894090
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: January 19, 2021
    Assignees: AGENSYS, INC., SEAGEN INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • ANTI SEZ6 ANTIBODIES AND METHODS OF USE
    Publication number: 20200181256
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: December 12, 2019
    Publication date: June 11, 2020
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, ROBERT A. STULL, MICHAEL TORGOV, HUI SHAO, DAVID LIU
  • DLL3 MODULATORS AND METHODS OF USE
    Publication number: 20200138969
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: December 6, 2019
    Publication date: May 7, 2020
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti SEZ6 antibodies and methods of use
    Patent number: 10533051
    Abstract: Provided are novel seizure related 6 (SEZ6) modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: January 14, 2020
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Laura Saunders, Scott J. Dylla, Orit Foord, Robert A. Stull, Michael Torgov, Hui Shao, David Liu
  • Anti-DLL3 antibody drug conjugates for treating cancer
    Patent number: 10478509
    Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: November 19, 2019
    Assignees: ABBVIE STEMCENTRX LLC, MEDIMMUNE LIMITED
    Inventors: Michael Torgov, Philip Wilson Howard
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS
    Publication number: 20190328898
    Abstract: Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: December 11, 2018
    Publication date: October 31, 2019
    Inventors: Michael TORGOV, Robert Kendall MORRISON, Aya JAKOBOVITS, Jean GUDAS, Zili AN
  • DLL3 MODULATORS AND METHODS OF USE
    Publication number: 20190247510
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 15, 2019
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • DLL3 MODULATORS AND METHODS OF USE
    Publication number: 20190046656
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: October 25, 2018
    Publication date: February 14, 2019
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti-DLL3 antibody drug conjugates for treating cancer
    Patent number: 10137204
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: November 27, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • NOVEL ANTIBODY CONJUGATES AND USES THEREOF
    Publication number: 20180318441
    Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
    Type: Application
    Filed: April 5, 2018
    Publication date: November 8, 2018
    Applicants: ABBVIE STEMCENTRX LLC, MEDIMMUNE LIMITED
    Inventors: Michael TORGOV, Philip Wilson HOWARD
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
    Publication number: 20180296693
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: April 2, 2018
    Publication date: October 18, 2018
    Inventors: Daulet SATPAYEV, Robert Kendall MORRISON, Karen Jane Meyrick MORRISON, Jean GUDAS, Aya JAKOBOVITS, Michael TORGOV, Zili AN
  • Anti-DLL3 antibody drug conjugates
    Patent number: 9968687
    Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: May 15, 2018
    Assignees: AbbVie Stemcentrx LLC, Medimmune Limited
    Inventors: Michael Torgov, Philip Wilson Howard
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 9962454
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: May 8, 2018
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • Anti-DLL3 antibody drug conjugates and methods of use
    Patent number: 9937268
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: April 10, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Methods of delivering DLL3 antibody drug conjugates
    Patent number: 9931421
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: April 3, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: RE48389
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: January 12, 2021
    Assignees: AGENSYS, INC., SEAGEN INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An